Top Nanotechnology Stocks To Consider – May 8th

OSI Systems, NVE, Clene, Biodexa Pharmaceuticals, Virpax Pharmaceuticals, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Nanotechnology stocks are shares of publicly traded companies whose core business involves research, development or manufacturing of materials and devices at the nanometer scale (one-billionth of a meter). These firms operate in fields like electronics, medicine, energy and materials science, where manipulating matter at the molecular level can yield novel properties or performance gains. Investing in nanotechnology stocks offers exposure to cutting-edge innovations but often carries higher volatility and long-term horizon risks. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

Shares of OSIS stock traded up $1.08 on Thursday, hitting $222.47. The company’s stock had a trading volume of 121,467 shares, compared to its average volume of 189,426. OSI Systems has a fifty-two week low of $129.18 and a fifty-two week high of $227.34. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.25 and a current ratio of 1.88. The stock’s 50 day moving average is $194.05 and its 200-day moving average is $181.10. The company has a market capitalization of $3.74 billion, a PE ratio of 28.63, a PEG ratio of 1.81 and a beta of 1.28.

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

Shares of NASDAQ NVEC traded up $8.04 during midday trading on Thursday, reaching $68.70. The company’s stock had a trading volume of 15,933 shares, compared to its average volume of 24,670. The company has a market cap of $332.30 million, a P/E ratio of 22.16 and a beta of 1.09. NVE has a fifty-two week low of $51.50 and a fifty-two week high of $89.98. The business’s 50 day moving average price is $61.57 and its two-hundred day moving average price is $71.74.

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Shares of CLNN traded up $0.05 during trading hours on Thursday, hitting $2.60. 40,989 shares of the company were exchanged, compared to its average volume of 78,298. The company has a market cap of $23.13 million, a price-to-earnings ratio of -0.49 and a beta of 0.46. The firm’s fifty day moving average is $3.43 and its 200 day moving average is $4.37. Clene has a fifty-two week low of $2.55 and a fifty-two week high of $9.20.

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Shares of NASDAQ:BDRX traded up $0.01 during midday trading on Thursday, hitting $1.39. The stock had a trading volume of 27,894 shares, compared to its average volume of 584,128. The company’s 50-day moving average price is $1.75 and its 200-day moving average price is $3.66. Biodexa Pharmaceuticals has a fifty-two week low of $1.14 and a fifty-two week high of $74.00.

Virpax Pharmaceuticals (VRPX)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

VRPX traded up $0.01 during trading on Thursday, hitting $0.25. 4,484 shares of the stock traded hands, compared to its average volume of 292,974. The business has a 50 day moving average price of $1.61 and a 200 day moving average price of $7.50. Virpax Pharmaceuticals has a twelve month low of $0.13 and a twelve month high of $84.75.

Clene (CLNNW)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Shares of Clene stock traded down $0.00 during trading on Thursday, reaching $0.03. 14,718 shares of the company’s stock were exchanged, compared to its average volume of 11,937. Clene has a 1-year low of $0.02 and a 1-year high of $0.08. The firm’s 50-day moving average price is $0.03 and its 200 day moving average price is $0.04.